Thailand Post-Market Obligations for Medical Devices

Thailand imposes genuine post-market obligations on medical devices, and the duty bearer is clearly identified: the Thai licence-holding entity. This page summarises who must report, what must be reported, which forms apply, which ongoing obligations continue after registration, and why responsibility cannot be shifted downstream to distributors or upstream to the original manufacturer.

1. Key takeaways

Yes, Thailand has post-market surveillance requirements for medical devices, and the obligation falls squarely on the Thai licensed entity. The legal basis is Section 41 paragraph 4 of the Medical Device Act B.E. 2551 (2008), as amended by the Medical Device Act (No. 2) B.E. 2562 (2019), with timeframes set by the MoPH Notification B.E. 2563 (2020). Reporting duties apply regardless of whether the defect or adverse event occurred inside or outside Thailand, and submissions to the Thai FDA must be made by the Thai licence holder in the Thai language.

• Duty bearer. The reporting obligation rests on the institutional registrant, the licence holder, the detailed notification holder and the notifier of the device, whether the defect or event occurred in Thailand or abroad. In practice this means the Thai entity named on the certificate. A foreign manufacturer may provide investigation findings and data, but the report submitted to the Thai FDA is filed by the Thai licence holder.
• Forms and channel. Reports use Thai FDA prescribed forms submitted to the Health Product Vigilance Center (HPVC), online or in person. Under HPVC industry guidance issued in February 2021, the forms are Ror Mor Por 1, 2 and 3, completed with IMDRF terminology codes in the problem and health effect fields. Reports must be completed in Thai; English supporting evidence is acceptable, but the primary submission must be in Thai.
• What must be reported. Two categories: device defects and adverse events arising from those defects. Details are set out below.
• Ongoing obligations. Five continuing duties survive registration, covering record keeping, licensing, labelling, documentation and compliance ownership.
• Non-transferability. Responsibility cannot be transferred to distributors or to the original manufacturer.

2. Legal basis

The reporting duty originates in Section 41 paragraph 4 of the Medical Device Act B.E. 2551 (2008), as amended by the Medical Device Act (No. 2) B.E. 2562 (2019). The operative timeframes for reporting device defects and adverse events, and for field safety corrective action reports, are set by the MoPH Notification on Criteria, Procedures and Conditions for Reporting Medical Device Defects or Adverse Events of Consumers and Field Safety Corrective Action Reports B.E. 2563 (2020), which took effect sixty days after publication and replaced the 2016 notification. The procedural details, including the forms and terminology codes, come from HPVC industry guidance published in February 2021. Read together, these instruments allocate the entire post-market duty chain to the Thai licence holder: detection, reporting, record keeping and compliance ownership all sit with the entity named on the registration, licence or notification document.

3. Expert insights

The scope of what must be reported is deliberately broad. A device defect covers malfunction; deterioration of the characteristics, quality or performance of the device; erroneous display or erroneous results; deviation from specification; design defects; labelling or instructions for use that are incorrect or incomplete; and use error arising from ergonomic features or inadequate information. An adverse event, in turn, is an event caused by such a defect that leads to, may possibly lead to, or contributes to the death or injury of a consumer.

Beyond defect and adverse event reporting, five continuing obligations apply. First, import and sales records must be retained for no less than five years. Second, a valid import or institutional licence must be maintained together with GDPMD, the Good Distribution Practice for Medical Devices. Third, products must be correctly labelled before distribution. Fourth, the quality, standards, performance and safety scientific documentation for registered products must be kept available for inspection. Fifth, post-market surveillance, vigilance reporting, labelling and advertising compliance are wholly the responsibility of the licence holder.

On the question of whether responsibility can be shifted to distributors or to the original manufacturer, the answer is no. The licence holder, whether manufacturer or importer, bears full responsibility for post-market surveillance, vigilance reporting and labelling and advertising compliance. Agreements may only allocate internal recourse between parties; external responsibility is non-transferable. This is consistent with the Thai structure in which the licence holder, the importer and the authorised representative are the same entity: power and duty are concentrated in a single body, so there is no third party to shift the burden onto.

4. Practical recommendations

• Build the post-market obligations into a single responsibility matrix before launch, spelling out five roles: who detects the issue, who determines the classification, who translates and files the report, who executes the recall, and who submits to HPVC.
• Write the statutory timeframes of 48 hours, 10 days and 30 days directly into the matrix and into the corresponding procedures, so the clock is visible to every function that participates in a report.
• Record the allocation of duties in the distribution or service agreements, understanding that such clauses only govern internal recourse and never transfer external responsibility away from the Thai licence holder.
• Treat records as the first line of compliance. Thai inspections typically start from records, and missing records are themselves a citable violation regardless of whether an actual adverse event has occurred.
• Maintain the five-year import and sales records, GDPMD evidence, pre-distribution labelling checks and the quality, standards, performance and safety documentation in an inspection-ready state at all times rather than assembling them after an inspection notice arrives.

5. Verification checklist

• □ Confirm the reporting duty under Section 41 paragraph 4 of the Medical Device Act B.E. 2551 (2008), as amended by the Medical Device Act (No. 2) B.E. 2562 (2019).
• □ Confirm the applicable MoPH Notification B.E. 2563 (2020) on criteria, procedures and conditions for reporting device defects or adverse events of consumers and field safety corrective action reports, effective sixty days after publication and replacing the 2016 notification.
• □ Confirm HPVC industry guidance of February 2021 on forms Ror Mor Por 1, 2 and 3 and IMDRF terminology codes.
• □ Confirm record retention of at least five years, maintenance of the institutional licence and GDPMD, correct labelling before distribution, and retention of quality, standards, performance and safety documentation.
• □ Confirm the principle that responsibility is non-transferable.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Thailand. Our team prepares dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with the Thai FDA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com